AbbVie - Stock Price History | ABBV

Historical daily share price chart and data for AbbVie since 2022 adjusted for splits. The latest closing stock price for AbbVie as of May 20, 2022 is 151.01.
  • The all-time high AbbVie stock closing price was 174.96 on April 08, 2022.
  • The AbbVie 52-week high stock price is 175.91, which is 16.5% above the current share price.
  • The AbbVie 52-week low stock price is 105.56, which is 30.1% below the current share price.
  • The average AbbVie stock price for the last 52 weeks is 128.80.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 113.0675 105.4100 135.9300 102.3000 135.4000 26.36%
2020 90.8994 89.5500 108.6700 64.5000 107.1500 21.02%
2019 77.9488 89.2300 90.7900 62.9800 88.5400 -3.96%
2018 97.4699 98.4100 123.2100 77.8500 92.1900 -4.67%
2017 75.1653 62.4100 98.2100 60.0000 96.7100 54.44%
2016 60.6680 57.6100 67.3900 51.1800 62.6200 5.71%
2015 62.1042 65.8900 71.2300 48.2700 59.2400 -9.47%
2014 55.4601 51.9800 69.7100 46.4600 65.4400 23.92%
2013 43.6623 35.1200 54.3200 33.7100 52.8100 0.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $266.851B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.706B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07